Insulin resistance has been present for years before fasting glucose crosses 100. Here is the test that finds it early.

Your patient's A1c is 5.4. Her fasting glucose is 96. Her lipid panel is unremarkable.

You tell her her metabolic labs look fine.

She leaves the visit feeling reassured. You move on to the next patient.

Six months later she is back. Her weight is up. She is more fatigued. Her fasting glucose is now 101. You order the same panel and tell her to watch her diet.

Here is what nobody ordered in either of those visits: fasting insulin.

And that is the test that would have changed everything.

Why Standard Metabolic Labs Miss Insulin Resistance

Fasting glucose and A1c measure the downstream consequences of insulin resistance. They tell you what happened after insulin stopped working effectively. By the time fasting glucose crosses 100 or A1c crosses 5.7, insulin resistance has typically been present for years.

Fasting insulin measures the upstream driver. It tells you how hard the pancreas is working to maintain that normal-looking glucose. A fasting glucose of 96 with a fasting insulin of 22 is not a normal metabolic picture. It is a pancreas working three to four times harder than it should to keep glucose in range.

That is insulin resistance. And it will not show up on a standard metabolic panel until the system is already significantly compromised.

How to Order and Interpret Fasting Insulin

Fasting insulin is a standalone lab add-on. It is not included in a standard CMP or BMP. You have to order it specifically.

Draw it fasting, ideally alongside a fasting glucose so you can calculate HOMA-IR.

Here is how to interpret the result in functional clinical practice:

• 2 to 5 microunits per milliliter: optimal
• 6 to 10 microunits per milliliter: early insulin resistance, worth monitoring and addressing with lifestyle
• 11 to 15 microunits per milliliter: moderate insulin resistance, warrants direct clinical intervention
• Above 15 microunits per milliliter: significant insulin resistance, active driver of metabolic dysfunction
• Above 20 microunits per milliliter: severe insulin resistance, likely present for years before this visit

Calculating HOMA-IR

Once you have fasting insulin and fasting glucose you can calculate HOMA-IR. The formula is:

Fasting insulin multiplied by fasting glucose divided by 405.

Here is how to interpret the result:

• Below 1.0: optimal insulin sensitivity
• 1.0 to 1.9: mild insulin resistance beginning
• 2.0 to 2.9: moderate insulin resistance, intervention indicated
• Above 3.0: significant insulin resistance, active metabolic driver
• Above 4.0: severe insulin resistance

A patient with a fasting glucose of 96 and a fasting insulin of 22 has a HOMA-IR of 5.2. That is not a patient with normal metabolic labs. That is a patient in the advanced stages of insulin resistance with a glucose that still looks fine on paper.

What Insulin Resistance Is Actually Driving

This matters beyond weight and blood sugar. Insulin resistance is a systemic metabolic driver that affects nearly every clinical presentation your integrative patients bring to you.

In your hormonal patients, insulin resistance drives androgen excess, disrupts the HPO axis, worsens estrogen dominance, and impairs thyroid conversion. The hormone patient who is not responding to BHRT often has unaddressed insulin resistance underneath.

In your GLP-1 patients, insulin resistance that predated the medication by years is one of the primary drivers of plateau. The medication cannot override a metabolic environment it was never designed to fix.

In your gut health patients, insulin resistance worsens intestinal permeability, drives systemic inflammation, and feeds the dysbiosis that is making the gut protocol slower to work than it should be.

In your brain health patients, insulin resistance impairs cerebral glucose uptake and is now recognized as a primary driver of cognitive decline. Some researchers refer to Alzheimer's disease as type 3 diabetes for this reason.

One lab. One result. A completely different clinical picture across every system you are treating.

What to Do When the Result Is Elevated

You are not diagnosing diabetes. You are identifying a metabolic pattern early enough to change the trajectory. Here is where to start:

1. Address dietary carbohydrate quality and timing. Not necessarily low carbohydrate but strategic carbohydrate. Front-load protein. Reduce refined carbohydrates and ultra-processed foods. Time carbohydrate intake around physical activity.
2. Prescribe resistance training specifically. Skeletal muscle is the primary site of glucose disposal. Building lean mass improves insulin sensitivity more reliably than cardio alone. Give a specific prescription, not a general recommendation.
3. Consider berberine. At 500 mg two to three times daily with meals, berberine has demonstrated insulin-sensitizing effects comparable to metformin in several clinical trials. It is a reasonable first-line supplement intervention for moderate insulin resistance in a patient who is not yet at the threshold for pharmaceutical intervention.
4. Address sleep. One night of partial sleep deprivation meaningfully raises fasting insulin the following morning. Poor sleep is not a lifestyle preference. It is a metabolic intervention point.
5. Reassess in 90 days. Fasting insulin responds to lifestyle intervention faster than A1c. A motivated patient with a solid protocol can move HOMA-IR meaningfully in 90 days. That early win changes the clinical relationship.

The Patient Who Needed This Test Years Ago

The patient sitting across from you who has been told her metabolic labs are fine for the past five years may have been living with significant insulin resistance the entire time. The downstream consequences are now showing up in her weight, her energy, her hormones, and her cognitive clarity.

One test. Ordered today. Changes what you see and what you can do about it.

That is the difference between managing consequences and addressing root causes.

If you want to go deeper on functional metabolic lab interpretation and how to build a complete metabolic clinical picture, the Metabolic Health and Insulin Resistance course at BridgeWell covers fasting insulin, HOMA-IR, advanced cardiometabolic markers, and the complete intervention framework.

Learn more here: https://www.bridgewelled.com/metabolic-medicine-bundle

Not ready for a course? Start with the BridgeWell Clinical Case Series: three real patient cases that show you integrative clinical thinking in action.

Access the case series here: https://www.bridgewelled.com/case-series